8-Bromoguanosine 3′,5′-cyclic monophosphate sodium salt  ≥98%

促销价¥{{model.attbuying.price}}

市场价¥0.00

累计销量0 累计评价0 人评论

别称 {{model.alias}}
中文名称 {{model.name}}
英文名称 {{model.enname}}
品牌 {{model.brand}}
CAS {{model.cas}}
分子式
分子量 {{model.molecularweight}}
MDL {{model.mdl}}
货号 {{model.procode}}
数量

+ -

库存{{model.attbuying.number}}
包装规格:5mg 10mg in glass bottle
产品简介:cGMP的膜渗透性类似物,是一种PKG激活剂。8-Bromo-cGMPsodium可显着抑制Ca2+宏观电流并损害高K+刺激的胰岛素释放。8-Bromo-cGMPsodium具有镇痛和血管舒张作用。
溶解性:溶于水(50mg/mL)
储备液保存:-80°C, 6 months -20°C, 1 month (sealed storage, away from moisture
体内实验:1、请依序添加每种溶剂: PBS Solubility: 100 mg/mL (224.18 mM); 澄清溶液; 超声助溶 <1mg/ml表示微溶或不溶。 普西唐提供的所有化合物浓度为内部测试所得,实际溶液度可能与公布值有所偏差,属于正常的批间细微差异现象。 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
体外研究:8-Bromo-cGMP sodium (1-100 μM; 8 h) increases resistance of LLC-PK1 cells to CsA toxicity concentration-dependently. 8-Bromo-cGMP sodium (1-100μM; 16h) induces the synthesis of HO-1 protein in a concentration-dependent fashion.
体内研究:8-Bromo-cGMP sodium (0.3,1, 3.0 nmol; intrathecal administration;10 min before test) dose-dependently and significantly increases the tail-flick latency in Vincristine-treated mice to the level observed in vehicle-treated naive mice (male ICR mice, 4weeks of age and weighing 20 g). Vincristine (0.05 mg/kg 1 day after the pre-drug tail-flick latency, and then 0.125 mg/kg twice a week for 6 weeks) can induce painful neuropathy in mice. 8-Bromo-cGMP sodium (10 mg/kg; iv; single dose) results in vasodilator responses in eNOS-Tg mice and WT littermates in C57BL/6 background (19-35 g).
保存条件:-20℃
注意事项:1、为了您的安全和健康,请穿实验服并戴一次性手套操作。 2、以上信息仅做参考交流之用。